Related Experiment Video

Updated: May 30, 2025

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies
09:08

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies

Published on: May 24, 2021

5.7K

Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling

Jing-Jing Zhang1,2, Xue-Rui Ye1,2, Xue-Song Liu3

  • 1Chinese Academy Medical Sciences, Fuwai Yunnan Hospital, Kunming 650000, Yunnan Province, China.

World Journal of Cardiology
|January 27, 2025
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, used for diabetes, show promise in treating pulmonary vascular diseases. They improve lung blood vessel function and reverse arterial remodeling by targeting glucose reabsorption.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Pulmonary Medicine

Background:

  • Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are oral antidiabetic drugs.
  • They work by inhibiting glucose reabsorption in the kidneys.
  • SGLT-2 inhibitors have demonstrated significant cardiovascular benefits.

Purpose of the Study:

  • To review the mechanisms by which SGLT-2 inhibitors impact pulmonary vascular cells.
  • To explore their potential in reversing pulmonary arterial remodeling.
  • To highlight their therapeutic implications for pulmonary vascular diseases.

Main Methods:

  • Comprehensive literature synthesis.
  • Analysis of basic science research on SGLT-2 inhibitors' effects on pulmonary vasculature.
  • Review of clinical investigations regarding cardiovascular and pulmonary outcomes.

Main Results:

  • SGLT-2 inhibitors enhance pulmonary vascular endothelial cell function.
  • They suppress pulmonary smooth muscle cell proliferation and migration.
  • These agents show potential in reversing pulmonary arterial remodeling and maintaining hemodynamic stability.

Conclusions:

  • SGLT-2 inhibitors offer a novel therapeutic approach for pulmonary vascular diseases.
  • Their mechanisms involve direct modulation of pulmonary vascular cells and arterial structures.
  • Further research is warranted to fully elucidate their role in managing these conditions.
Keywords:
Cardiovascular diseasePulmonary artery remodelingPulmonary vascular endothelial cellsPulmonary vascular smooth muscle cellsRight heart dysfunctionSodium-glucose cotransporter-2 inhibitors

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

339
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
574
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
117.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
164
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
462